We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We may also share information about your use of our site with our social media, advertising and analytics partners. Read more about our Privacy Policy.

I got it!

Annual Bispecific Antibody Lisbon Summit

The Curtis & Wyss Group is pleased to invite you to the, Annual Bispecific antibody Lisbon summit, scheduled on March 23-24, 2017 in Lisbon, Portugal.

This premier B2B event will focussed completely on the development of bispecifics Antibody, the Annual Bispecific antibody Lisbon summit represents a unique opportunity to engage with your peers to discuss strategies to overcome the key challenges holding back progress in the field. 

Built using insights from experts, this year’s Bispecific Antibody Lisbon summit will incorporate more developmental and clinical insights than ever before. Rather than presenting vague overviews of platforms, this meeting will delve directly into the technical and scientific insights that will enable you to advance your candidate therapeutic into the clinic as efficiently and cost-effectively as possible. 

 

Key Practical Learning Points of the Summit: 

  • Optimize early decision makingto guarantee target synergy early in the development of multispecific therapeutics, with insights into Sanofi’s novel bispecific development programs
  • Validate bispecific formats in comparison with monoclonal approachesby learning from innovative analytical approaches, including Janssen’s dual binding and single target assays
  • Understand how Pfizer have enhanced bispecific IgG generation by bypassing the need for post purification recombination processes
  • Improve translatability into the clinic by investigating how Immunocore maximize the predictability of in vitro models
  • Investigate novel multispecific approaches for applications spanning beyond oncology, including in- depth case studies into innovative bispecific programs in autoimmune, neurodegenerative and infectious disease indications
  • Determine the characteristics required to ensure clinical success by examining key factors from clinical bispecific programs at Merrimack, Amgen and Macrogenics
  • Leave World Bispecific with clear insights that will dramatically improve the success of your bispecific development

 

WHY should you be there?

CEO, CSO, VP, Director, Head and Scientists in: 

  • Bispecifics
  • Antibody/Biologics
  • R&D
  • Therapeutic Areas
  • Discovery
  • Target ID & Validation
  • Process Development
  • Manufacturing/CMC
  • Bioanalysis
  • PKPD/ADME/Tox
  • Clinical Development
  • Business Development

When

23 Mar 2017 @ 08:30 am

24 Mar 2017 @ 05:00 pm

Duration: 1 days, 8 hours


Where

Lisbon

Lisbon

13000 Lisbon

Portugal


Organised by

Curtis Wyss

Premium Events in Biotechnology

Recent Publications in Biotechnology

Recent Videos in Biotechnology

Recent News in Biotechnology

Celebrating 25y of #TEN_T & 10y of @INEA's success! #CEF has proven its #EU added value w/ €22.3bn to 641… https://t.co/rlvVIt9zct

@inea_eu - 25 Apr 2018 08:19

“Transport is the blood circulation of the economy” says Péter Bálasz, TEN-T European Coordinator. Important to tak… https://t.co/xv1lyk5XCx

@inea_eu - 25 Apr 2018 08:10

Just landed in #Ljubljana to join #TEN_TDays and open session on #aviation and #sesar tomorrow. Attractive agenda w… https://t.co/ZfWlVcam4w

@inea_eu - 25 Apr 2018 08:10

Recent Speakers in Biotechnology

Premium Eventslearn more ..